Table of Contents
Hepatitis Research and Treatment
Volume 2013 (2013), Article ID 653976, 6 pages
http://dx.doi.org/10.1155/2013/653976
Clinical Study

Evaluation of the Significance of Pretreatment Liver Biopsy and Baseline Mental Health Disorder Diagnosis on Hepatitis C Treatment Completion Rates at a Veterans Affairs Medical Center

1Department of Pharmacy, Philadelphia Veterans Affairs Medical Center, 3900 Woodland Avenue, Philadelphia, PA 19104, USA
2Department of Pharmacy, Hospital of the University of Pennsylvania, 3400 Spruce Street, Philadelphia, PA 19104, USA
3Gastroenterology Section, Philadelphia Veterans Affairs Medical Center, 3900 Woodland Avenue, Philadelphia, PA 19104, USA
4Division of Gastroenterology, University of Pennsylvania Perelman School of Medicine, 421 Curie Boulevard, 9th Floor, Philadelphia, PA 19104, USA

Received 30 January 2013; Revised 26 April 2013; Accepted 2 May 2013

Academic Editor: Tatehiro Kagawa

Copyright © 2013 Joseph Kluck et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. Williams, “Global challenges in liver disease,” Hepatology, vol. 44, no. 3, pp. 521–526, 2006. View at Publisher · View at Google Scholar · View at Scopus
  2. M. J. Alter, “Epidemiology of hepatitis C virus infection,” World Journal of Gastroenterology, vol. 13, no. 17, pp. 2436–2441, 2007. View at Google Scholar · View at Scopus
  3. G. L. Armstrong, A. Wasley, E. P. Simard, G. M. McQuillan, W. L. Kuhnert, and M. J. Alter, “The prevalence of hepatitis C virus infection in the United States, 1999 through 2002,” Annals of Internal Medicine, vol. 144, no. 10, pp. 705–714, 2006. View at Google Scholar · View at Scopus
  4. R. C. Cheung, “Epidemiology of hepatitis C virus infection in American Veterans,” American Journal of Gastroenterology, vol. 95, no. 3, pp. 740–747, 2000. View at Publisher · View at Google Scholar · View at Scopus
  5. J. A. Dominitz, E. J. Boyko, T. D. Koepsell, P. J. Heagerty, C. Maynard, and J. L. Sporleder, “Elevated prevalence of hepatitis C infection in users of United States veterans medical centers,” Hepatology, vol. 41, no. 1, pp. 88–96, 2005. View at Publisher · View at Google Scholar · View at Scopus
  6. K. L. Sloan, K. A. Straits-Tröster, J. A. Dominitz, and D. R. Kivlahan, “Hepatitis C Tested Prevalence and Comorbidities among Veterans in the US Northwest,” Journal of Clinical Gastroenterology, vol. 38, no. 3, pp. 279–284, 2004. View at Publisher · View at Google Scholar · View at Scopus
  7. M. G. Ghany, D. B. Strader, D. L. Thomas, and L. B. Seeff, “Diagnosis, management, and treatment of hepatitis C: an update,” Hepatology, vol. 49, no. 4, pp. 1335–1374, 2009. View at Publisher · View at Google Scholar · View at Scopus
  8. M. G. Ghany, D. R. Nelson, D. B. Strader, D. L. Thomas, and L. B. Seeff, “An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases,” Hepatology, vol. 54, no. 4, pp. 1433–1444, 2011. View at Publisher · View at Google Scholar
  9. G. M. Lauer and B. D. Walker, “Hepatitis C virus infection,” The New England Journal of Medicine, vol. 345, no. 1, pp. 41–52, 2001. View at Publisher · View at Google Scholar · View at Scopus
  10. G. Fattovich, G. Giustina, F. Degos et al., “Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients,” Gastroenterology, vol. 112, no. 2, pp. 463–472, 1997. View at Publisher · View at Google Scholar · View at Scopus
  11. T. Poynard, P. Bedossa, and P. Opolon, “Natural history of liver fibrosis progression in patients with chronic hepatitis C,” The Lancet, vol. 349, no. 9055, pp. 825–832, 1997. View at Publisher · View at Google Scholar · View at Scopus
  12. C. Global Burden of Hepatitis C Working Group, “Global burden of disease (GBD) for hepatitis C,” The Journal of Clinical Pharmacology, vol. 44, no. 1, pp. 20–29, 2004. View at Publisher · View at Google Scholar
  13. L. I. Backus, D. B. Boothroyd, B. R. Phillips, and L. A. Mole, “Predictors of response of U.S. veterans to treatment for the hepatitis C virus,” Hepatology, vol. 46, no. 1, pp. 37–47, 2007. View at Publisher · View at Google Scholar · View at Scopus
  14. B. A. Piasecki, J. D. Lewis, K. R. Reddy et al., “Influence of alcohol use, race, and viral coinfections on spontaneous HCV clearance in a US veteran population,” Hepatology, vol. 40, no. 4, pp. 892–899, 2004. View at Publisher · View at Google Scholar · View at Scopus
  15. H. S. Yee, S. L. Currie, J. M. Darling, and T. L. Wright, “Management and treatment of hepatitis C viral infection: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program Office,” American Journal of Gastroenterology, vol. 101, no. 10, pp. 2360–2378, 2006. View at Publisher · View at Google Scholar · View at Scopus
  16. G. L. Davis, R. Esteban-Mur, V. Rustgi et al., “Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C,” The New England Journal of Medicine, vol. 339, no. 21, pp. 1493–1499, 1998. View at Publisher · View at Google Scholar · View at Scopus
  17. E. J. Heathcote, M. L. Shiffman, W. G. E. Cooksley et al., “Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis,” The New England Journal of Medicine, vol. 343, no. 23, pp. 1673–1680, 2000. View at Publisher · View at Google Scholar · View at Scopus
  18. J. H. Hoofnagle and L. B. Seeff, “Peginterferon and ribavirin for chronic hepatitis C,” The New England Journal of Medicine, vol. 355, no. 23, pp. 2444–2451, 2006. View at Publisher · View at Google Scholar · View at Scopus
  19. J. G. Mchutchison, S. C. Gordon, E. R. Schiff et al., “Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C,” The New England Journal of Medicine, vol. 339, no. 21, pp. 1485–1492, 1998. View at Publisher · View at Google Scholar · View at Scopus
  20. S. Zeuzem, S. V. Feinman, J. Rasenack et al., “Peginterferon alfa-2a in patients with chronic hepatitis C,” The New England Journal of Medicine, vol. 343, no. 23, pp. 1666–1672, 2000. View at Publisher · View at Google Scholar · View at Scopus
  21. M. W. Fried, M. L. Shiffman, K. R. Reddy et al., “Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection,” The New England Journal of Medicine, vol. 347, no. 13, pp. 975–982, 2002. View at Publisher · View at Google Scholar · View at Scopus
  22. S. J. Hadziyannis, H. Sette, T. R. Morgan et al., “Peginterferon-α2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose,” Annals of Internal Medicine, vol. 140, no. 5, pp. 346–I67, 2004. View at Google Scholar · View at Scopus
  23. M. P. Manns, J. G. McHutchison, S. C. Gordon et al., “Peginterferon alfa-2b plus ribavirin compared with interferonalfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial,” The Lancet, vol. 358, no. 9286, pp. 958–965, 2001. View at Publisher · View at Google Scholar · View at Scopus
  24. V. L. Re, V. K. Amorosa, A. R. Localio et al., “Adherence to hepatitis C virus therapy and early virologic outcomes,” Clinical Infectious Diseases, vol. 48, no. 2, pp. 186–193, 2009. View at Publisher · View at Google Scholar · View at Scopus
  25. J. L. Dienstag, “The role of liver biopsy in chronic hepatitis C,” Hepatology, vol. 36, no. 5, pp. S152–S160, 2002. View at Publisher · View at Google Scholar · View at Scopus
  26. “Pegasys package insert,” September 2012, http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/103964s5204lbl.pdf.
  27. “Peg-Intron package insert,” September 2012, http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/103949s5217s5222lbl.pdf.
  28. “Ribavirin package insert,” September 2012, http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021511s023lbl.pdf.
  29. E. Dieperink, M. Willenbring, and S. B. Ho, “Neuropsychiatric symptoms associated with hepatitis C and interferon alpha: a review,” American Journal of Psychiatry, vol. 157, no. 6, pp. 867–876, 2000. View at Publisher · View at Google Scholar · View at Scopus
  30. M. W. Fried, “Side effects of therapy of hepatitis C and their management,” Hepatology, vol. 36, no. 5, pp. S237–S244, 2002. View at Publisher · View at Google Scholar · View at Scopus
  31. P. Hauser, “Neuropsychiatric side effects of HCV therapy and their treatment: focus on IFNα-induced depression,” Gastroenterology Clinics of North America, vol. 33, no. 1, pp. S37–S50, 2004. View at Publisher · View at Google Scholar · View at Scopus
  32. C. L. Raison, S. D. Broadwell, A. S. Borisov et al., “Depressive symptoms and viral clearance in patients receiving interferon-α and ribavirin for hepatitis C,” Brain, Behavior, and Immunity, vol. 19, no. 1, pp. 23–27, 2005. View at Publisher · View at Google Scholar · View at Scopus
  33. S. S. Liu, T. D. Schneekloth, J. A. Talwalkar et al., “Impact of depressive symptoms and their treatment on completing antiviral treatment in patients with chronic hepatitis C,” Journal of Clinical Gastroenterology, vol. 44, no. 8, pp. e178–e185, 2010. View at Publisher · View at Google Scholar · View at Scopus
  34. M. Huckans, A. Mitchell, S. Ruimy, J. Loftis, and P. Hauser, “Antiviral therapy completion and response rates among hepatitis c patients with and without schizophrenia,” Schizophrenia Bulletin, vol. 36, no. 1, pp. 165–172, 2010. View at Publisher · View at Google Scholar · View at Scopus
  35. B. T. Clark, G. Garcia-Tsao, and L. Fraenkel, “Patterns and predictors of treatment initiation and completion in patients with chronic hepatitis C virus infection,” Patient Preference and Adherence, vol. 6, pp. 285–295, 2012. View at Publisher · View at Google Scholar